Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- CSL Behring
- Study ID
- NCT03744910
- Phase
- PHASE3
- Status
- Terminated
Conditions
- Antibody-mediated Rejection
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Clazakizumab — BIOLOGICALClazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
- Physiologic saline solution — DRUGNormal saline
Study Details
This trial investigates the efficacy and safety of clazakizumab \[an anti-interleukin (IL)-6 monoclonal antibody (mAb)\] for the treatment of CABMR in recipients of a kidney transplant.
Key Dates
- Start date
- Oct 14, 2019
- Status verified
- Jul 2025
- Primary completion
- Apr 8, 2024
- Completion
- Apr 8, 2024
Study Design
- Enrollment
- 194 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: ClazakizumabClazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6 that is administered subcutaneously.
- Placebo Comparator: PlaceboPhysiologic saline solution that is administered subcutaneously.
Primary Outcome Measure
Change From Baseline to Week 52 in Estimated Glomerular Filtration Rate (eGFR) [ Time Frame: From Baseline to Week 52 ]
Locations (49)
Find similar trials in Birmingham, AL
By research site
University of Alabama at Birmingham (UAB) - University of Alabama Hospital (UAB Hospital)· Birmingham, ALMayo Clinic Hospital· Phoenix, AZCedars-Sinai Medical Center· Los Angeles, CAKeck Medical Center Of USC· Los Angeles, CAUCLA Kidney Transplant Research Program· Los Angeles, CAUniversity of California Davis Medical Center· Sacramento, CA
Related Studies
- Biorepository and Registry for Plasma Exchange PatientsRecruiting · Charles M Knudson · Iowa City, Iowa
- A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)PHASE2 · Recruiting · argenx · Birmingham, Alabama
- Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney TransplantationPHASE2 · Recruiting · Alexion Pharmaceuticals, Inc. · Birmingham, Alabama
- A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)PHASE3 · Enrolling By Invitation · Biogen · Los Angeles, California